Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-26-057942
Filing Date
2026-05-15
Accepted
2026-05-15 17:09:16
Documents
5
Period of Report
2026-05-15

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0291180-6k_xtlbio.htm 6-K 12475
2 NOTICE AND PROXY STATEMENT WITH RESPECT TO THE COMPANY'S EXTRAORDINARY GENERAL M ea029118001ex99-1.htm EX-99.1 82095
3 PROXY CARD FOR HOLDERS OF ORDINARY SHARES WITH RESPECT TO THE COMPANY'S EXTRAORD ea029118001ex99-2.htm EX-99.2 18745
4 GRAPHIC ea029118001_ex99-1img.jpg GRAPHIC 8835
5 GRAPHIC ea029118001_ex99-2img.jpg GRAPHIC 3215
  Complete submission text file 0001213900-26-057942.txt   131283
Mailing Address 26 BEN-GURION ST. RAMAT GAN L3 5112001
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3
Type: 6-K | Act: 34 | File No.: 001-36000 | Film No.: 26989668
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)